Loading...
XSHE300878
Market cap285mUSD
Jan 10, Last price  
14.00CNY
1D
-1.99%
1Q
-11.20%
IPO
-73.39%
Name

Zhejiang Wecome Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300878 chart
P/E
—
P/S
3.83
EPS
—
Div Yield, %
0.35%
Shrs. gr., 5y
4.22%
Rev. gr., 5y
-2.10%
Revenues
520m
-2.20%
135,059,810153,276,986207,742,355282,091,952406,528,838577,652,191641,800,892622,766,990632,953,240531,291,689519,621,071
Net income
-8m
L
19,748,01320,721,53050,023,69280,851,45095,157,72987,776,673126,012,754135,815,76096,495,37748,810,249-8,038,557
CFO
58m
-60.23%
25,982,10046,010,00029,632,900100,154,85129,003,913105,572,864112,762,18042,812,1900146,568,15058,289,136
Dividend
May 29, 20240.25 CNY/sh
Earnings
May 20, 2025

Profile

Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of pharmaceutical products. The company also offers healthcare products, over-the-counter products, and Chinese medicines. It offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Limited was founded in 2000 and is based in Lishui, China.
URL
https://www.zjwk.com/
IPO date
Aug 24, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
519,621
-2.20%
531,292
-16.06%
Cost of revenue
436,067
457,989
Unusual Expense (Income)
NOPBT
83,554
73,303
NOPBT Margin
16.08%
13.80%
Operating Taxes
399
12,631
Tax Rate
0.48%
17.23%
NOPAT
83,155
60,672
Net income
(8,039)
-116.47%
48,810
-49.42%
Dividends
(7,016)
(43,437)
Dividend yield
0.21%
1.21%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
261,904
269,003
Long-term debt
176,316
66,804
Deferred revenue
42,833
32,653
Other long-term liabilities
2
1
Net debt
81,505
136,388
Cash flow
Cash from operating activities
58,289
146,568
CAPEX
(139,285)
Cash from investing activities
9,313
Cash from financing activities
97,572
178,741
FCF
416,860
(302,101)
Balance
Cash
575,727
162,741
Long term investments
(219,012)
36,678
Excess cash
330,734
172,854
Stockholders' equity
661,629
730,754
Invested Capital
1,544,544
1,586,174
ROIC
5.31%
4.32%
ROCE
4.45%
4.15%
EV
Common stock shares outstanding
133,976
144,790
Price
25.36
2.26%
24.80
-15.42%
Market cap
3,397,630
-5.38%
3,590,800
-15.42%
EV
3,496,736
3,740,388
EBITDA
132,799
116,795
EV/EBITDA
26.33
32.03
Interest
9,450
5,410
Interest/NOPBT
11.31%
7.38%